

Press release August 29, 2018

Silurian Pharmaceuticals, Inc. Receives a Development Program Award from Cystic Fibrosis Foundation

07.30.00 PT Silurian Pharmaceuticals, Inc, received an award from the Cystic Fibrosis Foundation (CFF) for the development of its drug BREVENAL for the treatment of defective mucociliary clearance (MCC) in CF patients.

The award provides Silurian partial funding to complete investigational new drug (IND) enabling studies prior to launching human clinical testing. The funds will help Silurian to advance BREVENAL through the regulatory approval path.

BREVENAL is a drug with disease modifying potential as it improves defective mucociliary clearance and reverses bronchoconstriction, commonly experienced by CF patients. BREVENAL's effect is independent of the cystic fibrosis transmembrane conductance regulator (CFTR), the defective cause of CF disease. BREVENAL's activity is seen across CFTR mutations, including nonsense (X) mutations. BREVENAL is also additive in its effects to existing CFTR modulators.

“The award from the CFF is very significant for Silurian. It provides further support to the idea that BREVENAL may be an alternative approach to the treatment of CF patients. We are grateful for the CF Foundation's support and hope BREVENAL will help fulfil their mission to enhance the lives of CF patients,” said Dr. Cohen, CEO of Silurian Pharmaceuticals.

“There is a real need for novel disease modifying compounds to directly address the mucociliary dysfunction characteristic of CF, and the profile of BREVENAL, if confirmed in clinical studies, would be ideal for clinicians and patients to have on hand as an additional therapeutic option,” said Dr. Carlos Milla, Pediatric Pulmonologist and Director of the CF program at Stanford University and Lucille Packard Children's Hospital.

Silurian Pharmaceuticals, Inc., Emeryville, CA, designs and develops novel therapies for pulmonary disorders such as CF. Silurian's lead product is BREVENAL, a small molecule being developed as an inhaled product.

Investors & Media:

Dr Isaac Cohen, OMD PhD
Chief Executive Officer
+1 510 409 2894

Forward-looking statements This release may contain forward-looking statements, including statements regarding the anticipated timing of (pre-) clinical studies with BREVENAL and the progression and results of such studies, and the status and outcome of interactions with regulators. Silurian cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Silurian, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or

achievements expressed or implied by such forward-looking statements. In addition, even if Silurian' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing clinical trial with BREVENAL may not support registration or further development of BREVENAL due to safety, efficacy or other reasons), estimating the commercial potential of Silurian' product candidates.